1. Clofazimine does not lead to significant QT interval prolongation: a multicentre study.
- Author
-
Zweijpfenning SMH, van Groningen H, van Ingen J, Magis-Escurra C, Boeree MJ, Wagner D, Bax H, Andrejak C, Wener R, Rahman A, Kunst H, Lorent N, Brouwer MA, and Hoefsloot W
- Subjects
- Arrhythmias, Cardiac, Diarylquinolines, Heart, Humans, Clofazimine, Long QT Syndrome
- Abstract
Competing Interests: Conflict of interest: S.M.H. Zweijpfenning reports grants and non-financial support for a clinical trial from Novartis and Insmed, outside the submitted work. Conflict of interest: H. van Groningen has nothing to disclose. Conflict of interest: J. van Ingen has nothing to disclose. Conflict of interest: C. Magis-Escurra has nothing to disclose. Conflict of interest: M.J. Boeree has nothing to disclose. Conflict of interest: D. Wagner has nothing to disclose. Conflict of interest: H. Bax nothing to disclose. Conflict of interest: C. Andrejak has nothing to disclose. Conflict of interest: R. Wener has nothing to disclose. Conflict of interest: A. Rahman has nothing to disclose. Conflict of interest: H. Kunst has nothing to disclose. Conflict of interest: N. Lorent has nothing to disclose. Conflict of interest: M.A. Brouwer has nothing to disclose. Conflict of interest: W. Hoefsloot reports grants from Insmed Corp, during the conduct of the study.
- Published
- 2018
- Full Text
- View/download PDF